10-K: Mustang Bio Details Capital Structure and Regulatory Landscape in 10-K Filing

Mustang Bio's 10-K filing provides a detailed overview of its capital structure, voting rights, and regulatory environment, highlighting its focus on cell and gene therapies.

Summary

• Mustang Bio's 10-K filing outlines the company's authorized capital stock, including 200 million common shares and 2 million preferred shares.
• The document details the voting rights of common and preferred stockholders, with Class A Preferred Stock holding a voting majority.
• It explains liquidation rights, dividend policies, and the absence of preemptive or conversion rights for common stockholders.
• The filing also covers anti-takeover provisions, director liability, and indemnification, as well as special meeting and stockholder action procedures.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol MBIO.
• The document also includes details about the company's transfer agent and registrar, VStock Transfer, LLC.
• The filing also includes details about the company's various license agreements, clinical trial agreements, and sponsored research agreements with various institutions.
• The company has incurred significant losses since its inception and anticipates continued losses for the foreseeable future.
• The company has an accumulated deficit of $381.0 million as of December 31, 2023.
• The company is a majority-controlled subsidiary of Fortress Biotech, Inc.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with significant risks and challenges, particularly regarding the company's financial stability and the uncertainty of its product development pipeline. While there are some positive aspects, the overall tone is cautious due to the company's dependence on future funding and regulatory approvals.

Positives

• The company has established partnerships with world-class research institutions for its CAR T and gene therapy programs.
• The company has received Orphan Drug Designation for MB-106 for the treatment of Waldenstrom macroglobulinemia (WM).
• The company has received a safe-to-proceed approval from the FDA for its MB-109 IND application.
• The company is collaborating with the Mayo Clinic to develop a novel in vivo CAR T platform technology.
• The company has an ongoing partnership with LUMC for the development of additional LV gene therapies.

Negatives

• The company has incurred significant losses since its inception and anticipates continued losses for the foreseeable future.
• There is substantial doubt regarding the company's ability to continue as a going concern.
• The company has not generated any revenue from its development stage products.
• The company's short operating history makes it difficult to evaluate its business and prospects.
• The company's success is contingent on raising additional capital, and its efforts to do so may fail.
• The company has discontinued development of its MB-102, MB-103, MB-104 and MB-105 programs.

Risks

• The company's future growth and success depend on its ability to successfully develop and commercialize its product candidates, which it has yet to do.
• The company's future success is highly dependent on the successful development of its CAR T and gene therapy product candidates.
• Preclinical development is highly speculative and carries a high failure risk.
• The company may not receive the required regulatory approvals for any of its product candidates on its projected timelines, if at all.
• The company may not obtain the desired labeling claims or intended uses for product promotion, or favorable scheduling classifications, to successfully promote its product candidates, if approved.
• The company relies on third parties to conduct its preclinical studies and clinical trials, and those third parties may not perform satisfactorily.
• The company contracts with third parties for the manufacture of its product candidates for preclinical and clinical testing and may also do so for commercialization, if and when its product candidates are approved.
• The company relies on clinical data and results obtained by third parties, which may prove inaccurate or unreliable.
• The company may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
• The company is subject to anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and regulations.
• The company is subject to numerous environmental, health and safety laws and regulations.
• The company depends on its licensors to maintain and enforce the intellectual property rights covering certain of its product candidates.
• The company or its licensors may be subject to costly and time-consuming litigation for infringement of third-party intellectual property rights or to enforce its or its licensors intellectual property rights against third-party infringers.
• Fortress controls a voting majority of the company's common stock and has the right to receive significant share grants annually, which will result in dilution of the company's other stockholders.
• The company has entered into certain agreements with Fortress and may have received better terms from unaffiliated third parties.
• The company shares certain directors with Fortress, which could create conflicts of interest between the company and Fortress.
• The company may be unable to complete the sale of its manufacturing facility as contemplated if the Committee on Foreign Investment in the United States (CFIUS) determines to implement mitigation measures.
• The company's receipt of the contingent portion of the consideration for the sale of the manufacturing facility is subject to receipt of the consent of the landlord of the facility to the transfer of such lease to the buyer and the company's ability to raise additional capital.
• The landlord may object to certain aspects of the transaction, which could result in expensive and time-consuming litigation and could prevent the company from realizing the intended benefits of the transaction.
• If the sale of the facility is fully consummated, the company will rely on the buyer for the manufacture of its lead product candidates, which may subject the company to additional manufacturing risks.
• Certain key personnel may depart the Company upon the completion of the sale of the facility, which may adversely affect the company's ability to realize the anticipated benefits of the transaction.

Future Outlook

The company expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The company will need to obtain substantial additional financing and may choose to raise additional funds through strategic collaborations, licensing arrangements, public or private equity or debt financing, bank lines of credit, asset sales, government grants, or other arrangements.

Management Comments

• The company aims to acquire rights to technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and eventually either out-licensing or bringing the technologies to market.
• The company's pipeline is currently focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders.
• The company's strategy is to license technologies, support preclinical and clinical research activities by its partners, and transfer the underlying technology to its or its contract manufacturers cell processing facility in order to conduct its own clinical trials.

Industry Context

The document highlights the competitive landscape in the pharmaceutical and biotechnology industries, noting that many competitors have greater resources and experience. It also mentions the active field of CAR T therapy and the rapidly changing technologies in gene therapy, emphasizing the need for novel and unique treatments to compete successfully.

Comparison to Industry Standards

• The document notes that many competitors have significantly greater capital resources, larger research and development staffs and facilities and greater experience in drug development, regulation, manufacturing and marketing than Mustang Bio.
• The document lists several companies and partnerships currently engaged in clinical trials with CAR T modalities, including Bristol Myers Squibb, Novartis, AstraZeneca, Janssen Pharmaceutical Company, Gilead Sciences, Galapagos NV, Autolus Therapeutics, 2seventy bio, Kyverna Therapeutics, CARGO Therapeutics, ImmPACT Bio, and Cabaletta Bio.
• The document lists several companies currently engaged in developing gene therapies in various indications, including Abeona Therapeutics, Adverum Biotechnologies, Astellas, AVROBIO, Sio Gene, Biogen, bluebird bio, BioMarin Pharmaceutical, Krystal Biotech, MeiraGTx, Novartis Pharmaceuticals, Orchard Therapeutics, Passage Bio, Prevail Therapeutics, REGENXBIO, Rocket Pharmaceuticals, Roche, Sangamo Therapeutics, Sarepta Therapeutics, Solid Biosciences, Ultragenyx Pharmaceuticals, uniQure and Voyager Therapeutics.

Management Changes

Legal Proceedings

• The company has submitted a joint voluntary notice to the U.S. Committee on Foreign Investment in the United States (CFIUS) in connection with the sale of its manufacturing facility and associated assets to a third party. Such transaction is currently under review by CFIUS.

Related Party Transactions

• The company has entered into a Founders Agreement and a Management Services Agreement with Fortress Biotech, Inc.
• The company has entered into a Sub-Contracting CDMO Agreement with uBriGene.
• The company has entered into a Quality Services Agreement with uBriGene.
• The company has entered into a Transition Services Agreement with uBriGene.
• The company has entered into a Clinical Research Support Agreement with City of Hope.
• The company has entered into a Clinical Trial Agreement with Fred Hutchinson Cancer Center.
• The company has entered into a Sponsored Research Agreement with Mayo Clinic.
• The company has entered into a Sponsored Research Agreement with Leiden University Medical Centre.
• The company has entered into a Data Transfer Agreement with St. Jude Children's Research Hospital.

Stakeholder Impact

• Shareholders may experience dilution due to future capital raises and share grants to Fortress.
• Employees may be affected by changes in operations and potential departures following the sale of the manufacturing facility.
• Customers may be affected by changes in manufacturing and supply chain.
• Suppliers may be affected by changes in manufacturing and supply chain.
• Creditors may be affected by the company's financial instability and need for additional funding.

Next Steps

• The company expects to receive FDA feedback in an End-of-Phase 1 Meeting on its strategy to conduct a non-randomized registrational multicenter trial in relapsed or refractory WM in the first quarter of 2024.
• The company expects to treat the first patient in that trial in the second half of 2024, which could enable top-line results in the second half of 2026.
• The company anticipates requesting Regenerative Medicine Advanced Therapy (RMAT) designation for indolent lymphoma from the FDA in the first half of 2024.
• The company is currently evaluating the extent to which it can continue the development of MB-106 in other NHL subtypes, subject to allocation of resources.
• The company is currently evaluating the extent to which it can initiate the MB-109 study, subject to allocation of resources.
• The company is evaluating plans to file an IND application for a multicenter Phase 1 clinical trial for its in vivo CAR T platform technology once a lead construct has been identified, subject to allocation of resources.
• St. Jude intends to initiate a new Phase 1 trial in newly diagnosed infants using MB-117 in 2024.
• The NIH intends to initiate a new Phase 1 trial in previously transplanted patients using MB-217 in 2024.
• The company expects that additional centers will be added and that additional patients will be enrolled in the MB-110 trial in 2024.

Key Dates

Keywords

CAR T therapy, gene therapy, XSCID, RAG1-SCID, CD20, IL13R2, glioblastoma, biopharmaceutical, clinical trials, intellectual property, regulatory approvals, Fortress Biotech